Skip to main content
SLN
NASDAQ Life Sciences

10% Owner Sells $16.36M in Silence Therapeutics Shares Near 52-Week High

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$10.65
Mkt Cap
$499.742M
52W Low
$4.19
52W High
$11.06
52W Position info
154% above low
Off High info
3.7% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

SLN has more than doubled off its 52-week low of $4.19.

Summary

A 10% owner, Richard Ian Griffiths, sold over $16.3 million worth of Silence Therapeutics ADSs across multiple transactions, reducing his stake while the stock trades near its 52-week high.


Key Events · Ownership and Investor Activity · SLN

  • Significant Insider Sale

    Richard Ian Griffiths, a 10% owner, sold 1,544,374 American Depositary Shares (ADSs) for a total of $16,362,815.06.

  • Stake Reduction

    These sales represent approximately 13.06% of his prior holdings, reducing his post-transaction ownership to 10,281,486 shares.

  • Timing Near 52-Week High

    The transactions occurred between June 29 and July 6, 2026, while Silence Therapeutics' stock was trading near its 52-week high of $11.0599.


Analysis · SLN · Life Sciences

Richard Ian Griffiths, a 10% owner, executed significant sales of American Depositary Shares (ADSs) totaling over $16.3 million. These sales represent approximately 3.27% of the company's market capitalization and occurred over several days, coinciding with the stock trading near its 52-week high. While 10% owners often sell for portfolio rebalancing, the substantial size of these transactions, especially following recent positive clinical data and the activation of an At-The-Market offering program, could be interpreted negatively by the market as a lack of conviction at current price levels.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 32.4% of the 2199 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SLN was trading at $10.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $499.7M. The 52-week trading range was $4.19 to $11.06. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SLN - Latest Insights

SLN
Oct 19, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.80 info
Change: +$10.70 (+118%) info
Market Cap: $1.229B info
SLN
Oct 19, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.80 info
Change: +$10.70 (+118%) info
Market Cap: $1.229B info
SLN
Aug 14, 2026, 4:55 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.72
Real-time Price: $19.80 info
Change: +$6.08 (+44%) info
Market Cap: $1.229B info
SLN
Aug 13, 2026, 9:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $14.00
Real-time Price: $19.80 info
Change: +$5.80 (+41%) info
Market Cap: $1.229B info
SLN
Aug 13, 2026, 10:07 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $14.15
Real-time Price: $19.80 info
Change: +$5.65 (+40%) info
Market Cap: $1.229B info